The COVID-19 pandemic has made it clear how critical it is for society to have an efficient, well-trained, and coordinated response from the scientific community to address public health needs arising from the rapid emergence and spread of infectious disease.
Join Director George Painter of the Emory Institute for Drug Development and Associate Research Fellow Jamison Tuttle of Pfizer as they discuss the discovery and development of two successful COVID-19 orally available treatments, molnupiravir and nirmatrelvir. Register now to discover how this was accomplished as well as the scientific and organizational issues that impacted their unique processes.
This ACS Webinar is moderated by Christopher Cunningham of Concordia University Wisconsin School of Pharmacy and co-produced with the ACS Division of Medicinal Chemistry, the American Association of Pharmaceutical Scientists, and ACS Publications.
The recording of this webinar had to be taken down breifly. It will be posted again by March 2, 2022.
* If you are having technical difficulties viewing the video please try different internet browsers like Chrome, Firefox, and Explorer. If you still can not access the video please review the following computer prerequisites from our video hosting platform.
What You Will Learn
- Creating a target product profile
- Use of prodrugs to optimize drug uptake and distribution
- Role of tautomerization in the mechanism of action of molnupiravir The role SARS 2
- Main Protease Inhibitor plays in virus life cycle
- The key design concepts the led to a potent and oral bioavailable main Protease Inhibitor
- The pre-clinical profile and Phase I exposures of nirmatrelvir
;void(0);){kind=link}